Ambrose Healthcare acquires AM-Pharma in rare disease transaction worth up to €161 million
Ambrose Healthcare has acquired Netherlands-based AM-Pharma in a rare disease transaction worth up to €161 million, adding an investigational therapy for hypophosphatasia.
The acquisition gives Ambrose full ownership of AM-Pharma, its Phase II-ready ilofotase alfa programme and a European operating base in Utrecht, expanding the company's rare disease development activities.
Former AM-Pharma shareholders are eligible for an upfront payment, commercialisation-linked milestones and royalties on future sales, although the individual payment amounts have not been disclosed and the maximum transaction consideration remains contingent.
Field | Content |
Article Type | Deals |
Companies | Ambrose Healthcare; AM-Pharma |
Deal Type | Acquisition |
Acquirer | Ambrose Healthcare |
Target | AM-Pharma |
Target Country | Netherlands |
Ownership Acquired | 100% |
Transaction Status | Acquisition announced as completed |
Announcement Date | 20 October 2026 |
Maximum Transaction Consideration | Up to €161 million |
Payment Structure | Upfront payment plus commercialisation-linked milestones |
Upfront Payment | Amount not disclosed in supplied summary |
Milestone Payments | Commercialisation-linked; individual amounts not disclosed |
Royalties | Royalties on future sales; rates not disclosed |
Key Pipeline Asset | Ilofotase alfa |
Key Asset Development Stage | Phase II-ready |
Key Asset Indication | Hypophosphatasia |
Therapeutic Area | Rare diseases; metabolic bone disorders |
European Operating Base | Utrecht, Netherlands |
Geography | Netherlands; Europe |
What Happened | Ambrose Healthcare acquired 100% of AM-Pharma in a transaction with potential consideration of up to €161 million. |
Why It Matters | The acquisition adds an investigational rare disease treatment programme and establishes a European operating presence for Ambrose Healthcare. |
Strategic Rationale | Ambrose aims to expand its rare disease pipeline and European development capabilities through the acquisition. |
Potential Impact | The transaction may support further clinical development of ilofotase alfa for hypophosphatasia. |
Key Takeaway | Ambrose has acquired AM-Pharma and its Phase II-ready ilofotase alfa programme; the maximum €161 million consideration includes contingent payments. |
What to Watch | Ilofotase alfa Phase II development plans, clinical trial initiation, regulatory interactions and future commercialisation milestones. |
Primary Source | Ambrose Healthcare |
Primary Source URL | https://www.ambrosehc.com/news/ambrose-healthcare-acquires-am-pharma-for-up-to-%E2%82%AC161-million-expanding-its-rare-disease-pipeline-and-gaining-a-european-base |
Relevant Date | 20 October 2026 |
Discover how nuaxia can support your next medical education initiative:
Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector
Contact us on: support@nuaxia.com
留言